Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis
Open Access
- 1 November 2022
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2141973
Abstract
Immunogenic cell death (ICD) has been proposed to be a crucial process for antitumor immunosurveillance. ICD is characterized by the exposure and emission of Damage Associated Molecular Patterns (DAMP), including calreticulin (CRT). A positive correlation between CRT exposure or total expression and improved anticancer immunosurveillance has been found in certain cancers, usually accompanied by favorable patient prognosis. In the present study, we sought to evaluate CRT levels in the plasma membrane of CD38+ bone marrow mononuclear cells (BMMCs) isolated from 71 patients with varying degrees of multiple myeloma (MM) disease and examine the possible relationship between basal CRT exposure and the bone marrow immune microenvironment, as well as its connection with different clinical markers. Data show that increased levels of cell surface-CRT were associated with more aggressive clinical features and with worse clinical prognosis in MM. High CRT expression in MM cells was associated with increased infiltration of NK cells, CD8+ T lymphocytes and dendritic cells (DC), indicative of an active anti-tumoral immune response, but also with a significantly higher presence of immunosuppressive Treg cells and increased expression of PD-L1 in myeloma cells.Keywords
Funding Information
- European Regional Development Fund (SAF2016-76338-R)
- Gobierno de Aragón (B31_20R)
This publication has 64 references indexed in Scilit:
- Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevanceOncoTargets and Therapy, 2012
- Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple MyelomaPLOS ONE, 2012
- The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myelomaBritish Journal of Cancer, 2012
- Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemiaCell Death & Disease, 2010
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic DeathCancer Research, 2010
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibodyBlood, 2010
- Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myelomaBlood, 2010
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences, 2008
- The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapyImmunological Reviews, 2007